Received Nov 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | IM / RA |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | IM / LA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | IM / LA |
Patient presented with significant anxiety related to vaccine administration. After discussion with the medical assistant, the vaccine was administered. Immediately post-injection, the patient exhibited vasovagal symptoms, including diaphoresis, pallor, disorientation, and transient vision loss lasting approximately 3 minutes. Nursing assessment noted bilateral pupillary dilation. An attempt to obtain blood pressure was unsuccessful due to inability of the automated cuff to generate a reading. The patient was placed in a safe position and provided with oral fluids (water and juice) and crackers. Deep-breathing techniques were encouraged. Symptoms gradually resolved; pupillary size returned to baseline and the patient reported full restoration of vision without further complications.
None
None
None
NKA
N/A